These animal experiments preliminarily confirmed that spermidine as an adjuvant in immunotherapy represents a feasible therapeutic strategy, which can enhance anti-tumor immunity by promoting the activation of CD8+ T cells, thereby improving the efficacy of immunotherapy. Here, CD8A is linked to neoplasm.